Open access
Oct 2026
First-In-Human Study of 211At-CD45 Radioimmunotherapy With Nonmyeloablative Conditioning Hematopoietic Cell Transplantation for Adults With Hematologic Malignancies.
211At-CD45 RIT can be incorporated into nonmyeloablative conditioning, with liver toxicity defining activity limits, and evidence of antitumor efficacy supports phase II evaluation.
Phuong T. Vo, R. Walter, T. Gooley et al.
· Journal of Clinical Oncology · 0 citations